August 28,The Chinese Drug Clinical Trial Registry and Information Disclosure Platform shows that Hansoh Pharma has registered aType 2 DiabetesA Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects.InterceptImage source:Drug Clinical Trial Registry and Information Disclosure Platform
This is aMulticenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study, aiming to evaluate HS-20094 compared with placebo after 44 weeks of treatment in subjects with type 2 diabetes whose blood glucose control was poor despite simple dietary and exercise interventions.Effectiveness in Controlling Blood Sugar. The trial plans to enroll 204 people in China.HS-20094 is a glucagon-like peptide-1 developed independently by Hansoh Pharma.（GLP-1）And glucose-dependent insulinotropic polypeptide（GIP）Receptor dual agonist, which selectively activates GLP-1 receptor and GIP receptor, stimulates downstream pathways, and produces biological effects such as blood sugar control and weight reduction. Its method of administration isOnce a week, subcutaneous injection。In June 2025, Regeneron and Hansoh Pharma reached an agreement on this drug.License Agreement, awarded to RegeneronGlobal Exclusive License for the Development, Production and Commercialization of HS-20094(Excluding mainland China, Hong Kong and Macao)。According to the terms of this agreement, Hansoh willObtain$80,000,000The down payment, and is eligible to receive up to a certain amount based on the product's development, registration approval, and commercialization progress.$1.93 billionMilestone payments, as well as double-digit percentage royalties on potential future product sales.InterceptImage source: Insight DatabaseCover Source:Corporate LogoDisclaimer:This article is for information sharing only,不代表 Insight 立场和观点, and does not recommend or introduce any treatment options. If you have any needs, please consult and contact正规医疗机构.PR Article Collaboration: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
